The most relevant information about the biotechnology industry in some of the countries where we currently work.




  • Canada is a world leader in biotechnology (the bioeconomy) and has a large network of research hospitals, universities, laboratories, and companies that work within four major sectors: Bio-health, Bio-energy, Bio-industrial technology, Agri-biotechnology
  • Canada’s bioeconomy grew 12 per cent in 2012, standing as an $87 billion per year driver and representing 7 per cent of national GDP.
  • Biotechnology firms are in all the regions of Canada, with the highest number located in Quebec, followed by Ontario and British Columbia.
  • British Columbia has one of the largest biotechnology and life sciences sectors in Canada. The province plays an important role in the growing global life sciences industry.
  • The Canadian biotechnology industry consists of approximately 310 companies in the province of British Columbia only. Total estimated impact on provincial GDP: $1.03 billion
  • Three-quarters of Canadian biotechnology firms are concentrated in the health and/or the agri-food sector.
  • Biotechnology is a strong research-based sector with 1997 R&D expenditures of about $600 million.
  • Countries and companies around the world are investing billions of dollars in research and development to produce new products and processes.
  • As a key enabling technology for many areas of the Canadian economy, biotechnology can improve the quality and volume of products in the agriculture, fisheries and forest industries.
  • Biotechnology also has application in many other areas of Canadian society. It can improve the quality of life by providing new medicines, new tools for health surveillance and diagnosis, new foods, and solutions to problems as significant as climate change.
  • Biotechnology is one of the world’s fastest growing industries, in a growth rate 7.4%. It is expanding 4 times faster than the average for the economy. Global demand is expected to reach USD$727.1 billion by 2025.
  • About three quarters of world biotechnology demand will continue to be in the health sector with most of the remaining demand for biotechnology products to be in the agri-food sector.
  • Canada has strengths to build upon in both the health and agri-food areas.




  • In 2017 Mexico became the 17th country with most biotechnology businesses in the world.
  • Large international firms with biotechnology-related activities currently operate in Mexico, particularly in the agricultural area.
  • Mexico is experiencing a rapid growth in biotechnology applications to human healthcare, agriculture, marine resources, energy production and other areas.
  • Of the approximately 180 firms n 2017 that develop and/or use modern biotechnology in Mexico, 31% are in the agricultural area, 23% in environmental applica­tions, 18% in health care, 18% in food, and 10% in other areas.
  • Fifty percent of the country’s science researchers are involved in biotech, according to SIN, the country’s national association of researchers
  • Of the more than 140 research institutions in the country, 98 are engaged in biotech research.
  • Biotechnology has achieved its greatest use in agriculture, a sector in which viewpoints are polarized. Agriculture represents 5% of Mexico’s GDP, but more than 20% of the country’s population directly depends on the sector.
  • In 2017, at least 70 biotechnology development projects were identified in different states.
  • The states with clusters and presence of biotech business by application area n 2017 are: Nuevo Leon (6.5%), Guanajuato (5.1%), Mexico City (30.4%), Morelos (4.2%), Estado de Mexico (8.7%), Jalisco (12.1%) and Baja California an industrial and academic potential in biotechnology.
  • Ensenada is counting with a few research & development centers focusing mainly in areas such: Oceanology and Marine science, Optics and applied physics, Marine and agricultural biotechnology, Information & Communication technologies, Nanoscience and nanotechnology, etc.
  • Mexico is the 2nd country in Latin America with the highest number of patent applications.
  • In 2017 Mexico exported $11943 million dollars
  • Main exports destinations: United States, Brazil, China, Canada and Cuba.
  • Mexico is among the top 10 suppliers of biotech products to the United States.
  • Mexico has favorable conditions for biotechnological research and development thanks to its qualified human capital and specialized universities, research centers and laboratories.




  • The United States is the first country in the world where biotechnology was developed and represents approximately one third of the market.
  • Is the leading global biotech player, with over $112 billion U.S. dollars of revenue and the industry’s total market capitalization of some $700 billion U.S. dollars.
  • Its 2,270 companies generated revenues in 2017 of $106,000 million dollars and employed almost 309,000 people which meant an increase of 0.4% compared to 2016
  • It is expected that by 2022, there will be an internal demand of $ 124,216.50 million dollars, more than 2,533 companies and more than 326,182 jobs in this sector
  • The five states with the most biotechnology companies are California (19.3%), New York (5.6%), Florida (5.2%), New Jersey (5.1%) and Texas (5%). Together, these five states represent 40.2% of the establishments related to biotechnology.
  • Exports represented in 2017, $16,773 million dollars, the main destinations were, Belgium, China, Germany and Japan. They represent 15.7% of the revenue from the biotechnology industry
  • Imports satisfy 24.26% of demand, with a value of $28,857 million dollars in 2017, being the main suppliers of biotechnology in Ireland, Germany, Switzerland and India.
  • It is expected that by 2022 there will be revenues in the sector of $ 110,534.50 million dollars, exports will be $ 18,764.30 million dollars, imports will be $ 32,446.30 and domestic demand of $ 124,216.50 million dollars
  • 50% of the income of the biotechnology industry in the United States is generated by sales of health products.




  • A study done by CEBRAP (The Brazilian Center of Analysis and Planning) mapped 237 biotechnology companies in Brazil in 2017
  • São Paulo (SP) has a vast amount of those companies. The city represents 18% of all Brazilian biotech companies, while Belo Horizonte (MG) follows at 13%.
  • According to SINDUSFARMA (The Syndicate of the Pharmaceutical Products Industry in the State of São Paulo) in 2017 the Brazilian biopharmaceutical and biotechnology market was worth about USD$ 18 billion.
  • A recent survey conducted by Biominas (2017), revealed the general profile of Brazilian biotechnology companies. Most of them (about 60%) are small-sized, with up to 10 employees, and young. Nearly 70% of the companies have already made international cooperation and all the interviewees showed interest in carrying out future cooperation activities.
  • Human health represents 40% of companies; animal health, 15%; reagents, 14%; agriculture, 10%; environment, 10% and bioenergy at 8%
  • Brazil is currently the largest healthcare market in Latin America, covering almost one-fourth of the population.
  • Brazil is valued as a leader in industrial biotechnology and is known for their investment and R&D in cellulosic sugars and biofuels, there is a portion of the biotech market that is focused on human health.
  • Brazil is now the second-largest producer of biotech crops in the world
  • China is the largest destination of Brazilian exports, mostly soybeans. In 2017, total Brazilian agricultural exports to China reached US$24 billion, of which US$20 billion were soybeans and products.
  • Brazil exported to the United States US$4.5 billion in agricultural commodities and food products and imported US$1.4 billion of the same.